Long noncoding RNAs (lncRNAs) constitute one of the largest classes of transcripts and have been widely implicated in various diseases such as cancer. Increasing evidence suggests that several lncRNAs are dysregulated and play critical roles in tumorigenesis. LncRNAs can be regulated by key oncogenes and tumor suppressors, adding complexity to the intricate crosstalk between protein coding genes and the noncoding transcriptome. In our study, we investigated the effect that dysregulation of the key tumor suppressor PTEN has on the noncoding transcriptome. We identified the lncRNA metastasis associated lung adenocarcinoma transcript 1 (MALAT1) as a target of PTEN and find that this regulation is conserved in both human and mouse as well as with both chronic and acute PTEN dysregulation. We show that this regulation is at least in part microRNA (miRNA)-dependent, and characterize the miRNAs that may be mediating this crosstalk. In summary, we establish and characterize a non-canonical PTEN-microRNA-MALAT1 axis that regulates tumorigenesis and describe for the first time that the MALAT1 lncRNA possesses novel tumor suppressive properties in colon and breast cancers.
Introduction
Long noncoding RNAs (lncRNAs) represent one of the largest classes of transcripts and display a diverse range of properties and functions. In recent years, novel lncRNA transcripts have been identified at a rapid pace and increasing evidence has pointed to their crucial roles in various biological processes. 1, 2 Studies have also revealed their tissue-specific expression profiles 3 and frequent dysregulation in pathological conditions such as cancer. 4 The regulation of lncRNA expression has been shown to involve core transcription factors such as p53, NF-jB and Sox2 as well as b-catenin, 5, 6 most of which are key oncogenes and/or tumor suppressors well-established to play critical roles in tumorigenesis.
One of the most well-characterized tumor suppressor genes is phosphatase and tensin homolog (PTEN), first identified in the frequently deleted chr10q23 locus. 7 Over the past decade, mutations and disruptions of the PTEN gene have been widely observed in a wide spectrum of sporadic cancers as well as in cancer predisposition syndromes. 7, 8 Aside from its key function as a negative regulator of the proto-oncogenic PI3K/Akt/ mTOR pathway, 9, 10 PTEN has also been shown to localize to the nucleus where it performs crucial phosphatase-independent functions. 11, 12 In addition to these coding-dependent roles of PTEN, recent studies have revealed a novel coding-independent function of PTEN, whereby the PTEN transcript can act as an endogenous microRNA (miRNA) sponge to co-regulate the expression of coding and noncoding transcripts that containing binding sites for shared miRNAs, thus functioning as a competing endogenous RNA (ceRNA). [13] [14] [15] Several studies have described PTEN ceRNA activity in multiple cancers including prostate and colon cancers, melanoma and glioblastoma. [13] [14] [15] [16] Apart from the PTEN pseudogene (PTENP1), which is highly homologous to its parental gene and shares multiple identical microRNA response elements (MREs), the PTEN ceRNAs identified thus far have been largely limited to protein-coding messenger RNAs (mRNAs), [13] [14] [15] [16] with only a handful examples of noncoding transcripts exhibiting such activity. 17 Aside from protein-coding transcripts and pseudogenes, other classes of noncoding RNAs such as long noncoding RNAs (lncRNAs) and circular RNAs (circRNAs) have been shown to exhibit miRNA sponging activity that is of functional and biological relevance in various physiological and pathophysiological conditions. [18] [19] [20] For example, sponging of miR-133 and miR-135 by the muscle-specific lncRNA linc-MD1 was found to maintain the expression of transcription factors MAML1 and MEF2C, which regulate the activation of the muscle differentiation program in myoblasts. 18 In human embryonic stem cells, lncRNA linc-RoR was demonstrated to sponge miR-145 and prevent the downregulation of key transcriptional factors such as Oct-4, Nanog and Sox2, which are critical for the maintenance of the pluripotent state. 19 In our study, we examined the effect of PTEN dysregulation on the noncoding transcriptome and identified the lncRNA metastasis associated lung adenocarcinoma transcript 1 (MALAT1) as a downstream target of PTEN. We observed that this regulation is conserved upon chronic and acute PTEN perturbation in both human and mouse. We revealed the miRNA dependency of this regulation and identified the miRNAs that may be mediating this crosstalk. Furthermore, we found that MALAT1 exerts a modulatory effect on pro-migratory markers such as epithelial cell adhesion molecule (EpCAM) and integrin b 4 (ITGB4), suggesting a potential mechanism for MALAT1-mediated regulation of tumorigenesis. In summary, we establish and characterize a PTEN-miRNA-MALAT1 axis that regulates migration and invasion, and describe for the first time that the MALAT1 lncRNA possesses novel tumor suppressive properties in colon and breast cancers.
Materials and Methods

Reagents
Reagents are as follows: anti-HSP90 antibody (Santa Cruz); anti-GAPDH antibody (Santa Cruz); anti-PTEN antibody (Cell Signaling); anti-EPCAM antibody (Abcam); anti-INTEGRIN b4 (Cell Signaling); miRIDIAN microRNA mimics for nontargeting control (NC) and miRNAs (17-5p, 20a-5p and 106 b-5p), biotinylated microRNA reagents (NC1, NC2, 17-5p, 20a-5p and 106 b-5p), siGENOME siRNA reagents for nontargeting control (siNC) and PTEN (siPTEN), SMARTpool siRNA reagents for non-targeting control (siLNC1) and MALAT1 (siMALAT1), Dharmafect 1 (Dharmacon); Trizol LS, Lipofectamine 3000, Dulbecco's modified Eagle medium (DMEM), Roswell Park Memorial Institute 1640 medium (RPMI), OptiMem reduced serum media, fetal bovine serum (FBS), Dynabeads M-280 Streptavidin (Life Technologies); psiCHECK-2 vector (Promega); MALAT1 locked nucleic acid (LNA) fluorescein-labelled probe (Qiagen) and miRNAs LNA DIG-labelled probes (Exiqon). Tissue total RNA (5 mg) of 9 matched-pair human colorectal cancer (CRC) samples were purchased from Origene.
Cell culture and transfection
HCT116 and RKO cells were grown in DMEM supplemented with 10% FBS, penicillin/streptomycin and glutamine. SKBR3 cells were grown in RPMI 1640 Medium supplemented with 10% FBS, penicillin/streptomycin and glutamine. All cells were grown at 378C in a humidified atmosphere with 5% CO 2 . For the transfection of siRNAs and miRNA mimics, cells were transfected with 50 nM of each reagent per well using Dharmafect 1 in 12-well dishes as per the manufacturer's instructions. A seeding density of 150,000 cells per well was used for HCT116 and RKO cells and 200,000 cells for SKBR3. For plasmid transfection, HCT116/RKO and SKBR3 cells were seeded in 12-well dishes at a density of 100,000 and 150,000 cells per well, respectively. Transfection was performed after 24 hr with Lipofectamine 3000 following the manufacturer's protocol.
RNA extraction and real-time quantitative PCR
For real-time PCR analyses, total RNA was extracted using Trizol reagent and column purification using the PureLink RNA Mini Kit (Ambion). cDNA was generated using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) and real-time quantitative PCR was later performed using the 7900HT Fast or QuantStudio 5 Real-Time PCR System (Applied Biosystems).
Protein extraction and Western blot analysis
Cells were harvested and cell pellets were washed in ice-cold PBS before lysing on ice for 15 min with protein lysis buffer [10 mM Hepes pH 7, 0.1 M KCl, 5 mM MgCl2, 25 mM EDTA pH 8, 0.5% (v/v) NP-40, 20 lM DTT, supplemented with Proteinase Inhibitor (Roche)]. Lysates were pre-cleared by centrifugation at 16,000g for 15 min at 48C and protein concentrations were measured using Bradford Protein Assay (Bio-Rad). For western blot analysis, sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) was used to fractionate 10 lg of proteins by size in 4-12% Bis-Tris acrylamide NuPAGE gels in 3-(N-Morpholino)propanesulfonic acid (MOPS) SDS running buffer (Invitrogen) and transferred to polyvinylidene fluoride (PVDF) membranes (Thermo Scientific) in NuPAGE transfer buffer What's new? Long noncoding RNA (lncRNA) transcripts serve critical roles in biological processes. As a consequence, their dysregulation is implicated in various diseases, including cancer. In this investigation of tumorigenic effects of the noncoding transcriptome, the lncRNA metastasis associated lung adenocarcinoma transcript 1 (MALAT1) was identified as a PTEN tumor suppressor target, with its regulation occurring in a microRNA-dependent manner. In colorectal and breast cancer patients, MALAT1 and PTEN transcripts are downregulated and associated with reduced survival. Meanwhile, in colon and breast cancer cells, MALAT1 knockdown was associated with enhanced migration and invasion capabilities. The findings offer insight into the context-specific tumor-associated characteristics of lncRNAs.
(Invitrogen). The membranes were probed with primary antibodies as specified above in the reagent list.
Cell proliferation assay
Twenty-four hours post-transfection, cells were trypsinized and collected in 5.5 ml DMEM. Cells were then split into five 12-well dish. Upon adherence, cells were then fixed using 10% neutral-buffered formalin solution (Sigma-Aldrich, Cat. No. HT501128-4 L) and labeled as day 0. Subsequently, cells were fixed daily from days 2 to 5 before they were stained with crystal violet (Sigma-Aldrich, Cat. No. C0775-100 G). Cells were then washed at least three times with MilliQ water before leaving to dry. Into each well, 10% acetic acid (SigmaAldrich, A6283-2.5 L) was added to re-solubilize the crystal violet stain. Absorbance of the stain was read at 595 nm.
CellTiter-glo assay
Measurements were made according to manufacturer's instructions. Briefly, transfected cells were removed from the incubator and left to equilibrate at room temperature for 20 min. Equal volume of CellTiter-Glo reagent was added directly to the wells and the plates were incubated at room temperature for 30 min on a shaker. Luminescence was then measured and quantified using the Tecan infinite M200 plate reader (Life Sciences).
Soft agar assay
A 0.6% agarose base was prepared in six-well dishes. At 24 hr post-transfection, HCT116, RKO and SKBR3 cells were trypsinized, resuspended and counted. Seeding densities of 20,000 cells and 25,000 cells per well were used for HCT116/RKO and SKBR3, respectively. The cells were mixed with growth medium and agarose to a final agarose concentration of 0.3% and were added above the base. The cells were grown at 378C in a humidified atmosphere with 5% CO 2 and were fed with growth medium every 2 days. After 10-14 days, the colonies were imaged under 34 magnification and quantified using ImageJ.
Transwell migration and invasion assay
Cell invasion and migration assays were performed using HCT116 and SKBR3 cells. Cell culture was performed in transwell chambers (Corning, NY). Cells (2 3 10 5 ) were added to the upper chambers with insert membranes (coated with Matrigel for invasion assay; non-Matrigel coated for migration assay) and were cultured for 48 hrs. Cells were then fixed with 10% neutral buffered formalin solution (Sigma-Aldrich, Cat. No. HT501128-4 L) before they were stained with crystal violet (Sigma-Aldrich, Cat. No. C0775-100 G). Cells were subsequently washed with MilliQ water before cutting out the insert membranes. The migrated cells were photographed under an inverted microscope. 10% acetic acid (Sigma-Aldrich, A6283-2.5 L) was added to the membranes to re-solubilize the crystal violet stain. Absorbance of the stain was read at 595 nm.
Radius 24-well cell migration assay
Cell migration was assessed using a Radius 24-Well Cell Migration Assay Kit (Cell Biolabs) performed according to the manufacturer's instructions. Each well contains a circular 680-lm-diameter "gel spot" that cells do not adhere. Before the experiment, HCT116 cells were cultured to confluence. At the start of the experiment (i.e., time point 0 hr), the gel spot was digested and washed with PBS before adding 500 ml of culture media to the wells. Following which, siRNAs against MALAT1 were added to the wells and the cells were incubated at 378C to allow migration and population of the circular void space. After a 32-hr incubation, migrated cells were stained with crystal violet and captured using phasecontrast microscopy.
Wound healing assay
Wound healing ability was assessed using a CytoSelect 24-well Would Healing Assay kit (Cell Biolabs) performed according to the manufacturer's instructions. Before the experiment, HCT116 cells were cultured to confluence. At the start of the experiment (i.e., time point 0 hr), the inserts were removed and wells were washed twice with PBS to remove unattached cells and debris. Culture media (500 ml) was added to the wells alongside siRNAs against MALAT1. Cells were then incubated at 378C to allow the closure of the induced wound. After a 16-hr incubation, migrated cells were stained with crystal violet and captured using phase-contrast microscopy.
Biotinylated-miRNA pulldown assay
Pulldown experiments in HCT116, RKO and SKBR3 cells with control miRNA (NC), and miR-20a-5p, miR-17-5p and miR-106b-5p biotinylated mimics (Dharmacon), were conducted as described in the article by Lal et al. 21 RNA extracted from streptavidin beads using Trizol LS was further purified using phenol: chloroform:isoamyl (25:24:1) and chloroform:isoamyl (24:1) (Sigma).
Dual-luciferase reporter assay
Cells were seeded at density of 40,000 cells per well in a 24 wells-dish 1 day before transfection. Plasmids were transfected into the cells using Lipofectamine 3000 reagent. DNA mixture used for transfection contains 2 ll Lipofectamine 3000 (Life Technologies, Cat. No. L3000015), 150 ll optiMEM (ThermoFisher Scientific, Cat. No. 31985070) media and required concentration of plasmids. Ten nanograms of empty psicheck2 vector or psicheck2 cloned with MREs downstream of renilla luciferase construct were co-transfected together with 20 nm of miRNA mimics to the cells. The mixture was incubated at room temperature for 5 min and then added to the cell media. Cells were harvested 72 hrs post transfection and lysed with 100 ll of 13 passive lysis buffer. Lysate (20 ll) was used for analysis according to manufacturer's protocol (Promega, Cat. No E1960).
RNA fluorescent in situ hybridization
To detect lncRNA MALAT1, miR-17, 20a and 106b, HCT116 cells were rinsed in PBS and fixed in 4% paraformaldehyde and 4% sucrose in PBS (pH 6.9) at 48C overnight. Cells were then dehydrated and rehydrated in a series dilution of methanol before treatment with proteinase K (10 mg/ml) for 10 sec. Following which, cells were washed with PBS before incubated with hybridization buffer (HYB1) containing 50% deionized formamide containing 5XSSC, 0.1% Tween20, 50 mg/ml heparin, 500 mg/ml yeast tRNA for 2-6 hrs at the recommended hybridization temperatures (probe Tm-22.58C). Hybridization with the MALAT1 LNA probe (Qiagen) and miRNAs LNA probes (miRCURY LNA microRNA ISH Optimization Kit, Exiqon) was then carried out by incubating the cells by diluting with HYB1 buffer to recommended concentrations (miRCURY LNA microRNA ISH Optimization Kit, Exiqon) in a humidified chamber overnight at probe Tm-22.58C. After a series of washes, inactivation of endogenous peroxidase was performed by incubating the cells in 0.1 M glycine (pH 2.2) for 1 hr at room temperature. For miRNA detection, DIG-labeled probes were incubated with anti-DIG-HRP conjugated antibody (PerkinElmer). As for MALAT1 detection, fluorescein-labeled probe was incubated with anti-FAM-HRP conjugated antibody (PerkinElmer). Following which, signal amplification was performed using the TSA technology (TSA Plus Fuorescence kit, PerkinElmer). Fluorescence images of the cells were acquired along the z-axis using the Olympus FV1200 confocal microscope (1003 magnification) and processed using the Olympus FluoView FV1200 and ImageJ software.
MRE prediction
MRE predictions were performed using RNA22 which is available at https://cm.jefferson.edu/rna2226.
Statistical analysis
Unpaired Student's t test was used to analyze the experimental data, with mean 6 SD derived from three or more independent experiments. Values of p < 0.05 were considered as statistically significant. *p < 0.05; **p < 0.01; ***p < 0.001.
Results
PTEN loss leads to the downregulation of several long noncoding RNAs
To date, the majority of studies investigating miRNA sponging activity of the PTEN transcript have focused on transient knockdown experiments in human cell lines. To identify conserved lncRNA transcripts that are significantly dysregulated upon the stable loss of PTEN, we first examined the expression profile of lncRNAs in PTEN null (Pten -/-) and PTEN hypermorphic (Pten hy/1 ) mouse embryonic fibroblasts in publicly available datasets. 22, 23 PTEN transcript expression in these cells was 50% and 80% compared to that of the respective wild-type fibroblasts (Figs. 1a and 1b) . We found that transcripts of the lncRNAs DNM3OS, MALAT1, MEG3 and NEAT1 transcripts were significantly downregulated in these cells with stable loss of PTEN expression (Figs. 1a and 1b) . Next, to identify candidates that were responsive to PTEN perturbation in both human and mouse cells, we investigated the expression of these lncRNA candidates in PTEN heterozygous (Pten6) HCT116 human colorectal cancer cells. Realtime PCR analysis demonstrated that the MALAT1 transcript was significantly downregulated in the PTEN heterozygous state (Fig. 1c) . There was no significant change in DNM3OS or NEAT1 transcript levels, and the MEG3 transcript was not expressed at detectable levels (Fig. 1c) .
We examined the expression of MALAT1 and PTEN in CRC and found that both PTEN and MALAT1 transcripts were significantly downregulated in colon cancer samples relative to normal colon, in seven independent datasets ( Figs. 1d and 1e ; Supporting Information Figs. 1a-1c) (GSE38026) . [24] [25] [26] [27] [28] [29] Furthermore, a significant positive correlation between PTEN and MALAT1 expression was observed in all seven datasets ( Fig. 1f;  Supporting Information Figs. 1a and 1b, bottom panels, 1c) and decreased expression levels of MALAT1 and PTEN are significantly associated with lower chance of survival/increased mortality in CRC patients (p 5 0.00528 and p 5 0.018874 for MALAT1 and PTEN, respectively) (GSE17537). In addition, qPCR analysis of MALAT1 expression confirmed that its expression was significantly reduced in CRC compared to adjacent normal tissue in clinical patient samples (Fig. 1g) .
To evaluate whether this PTEN:MALAT1 regulation extends to other cancer types, we examined the effect of stable PTEN knockdown in three human cancer cell lines. 30 Consistent with the observed effect in colon cancer cells, PTEN knockdown also led to a corresponding downregulation of MALAT1 in SKBR3 breast cancer cells (Supporting Information Fig. 2a) . PTEN knockdown had no effect on MALAT1 transcript in A431 epidermoid carcinoma cells (Supporting Information Fig. 2a) . Interestingly, PTEN knockdown significantly increased MALAT1 expression in HCC827 lung adenocarcinoma cells (Supporting Information Fig. 2a) , consistent with the well-established oncogenic role for MALAT1 in lung cancer and indicating the cancer-type specificity of this potential PTEN:MALAT1 regulation.
Consistent with their expression levels in human colon cancer samples, PTEN and MALAT1 transcripts were significantly downregulated and exhibited a significant positive correlation in different subtypes of breast cancer (Supporting Information Figs. 2b and 2c) . Furthermore, high levels of MALAT1 were associated with increased survival (Supporting Information Fig. 2c ). Based on these findings, we hypothesized that the potential regulation of MALAT1 transcript by PTEN may represent a novel tumor suppressive axis in colon and breast cancers.
PTEN regulates MALAT1 expression in a microRNAdependent manner
To further investigate this, we performed a series of knockdown experiments using siRNAs against PTEN and MALAT1 transcripts in HCT116 and RKO colorectal cancer cells as well as SKBR3 breast cancer cells. We first investigated the endogenous levels of PTEN and MALAT1 in these cell lines and found that there were no significant differences in abundance of these transcripts across these cell lines (Supporting Information Fig. 3a) .
Knockdown of the PTEN transcript resulted in a significant downregulation of the MALAT1 transcript in wild-type HCT116, RKO and SKBR3 cells (Figs. 2a and 2b) . These effects were significantly abrogated in Dicer mutant (Dicer Ex5 ) cells that exhibit defective miRNA processing (Fig. 2a) , suggesting that the observed effects are at least partially miRNA dependent.
Next, we performed overexpression experiments with different parts of the PTEN transcript to shed light on the mechanism by which PTEN may regulate MALAT1. Overexpression of the PTEN coding sequence did not have any significant effect on MALAT1, suggesting that the observed regulation is not dependent on the PTEN protein or the protein-coding region of the PTEN mRNA (Supporting Information Fig. 3b ). The overexpression of the PTEN 3 0 UTR, however, resulted in a significant increase in MALAT1 transcript level in wild-type HCT116, RKO and SKBR3 cells (Figs. 2c and d) . These effects were significantly abrogated in Dicer mutant (Dicer
Ex5
) cells that exhibit defective miRNA processing (Fig. 2c) , suggesting that the observed effects are at least partially miRNA dependent.
However, although knockdown of the MALAT1 transcript resulted in a small but significant decrease in PTEN transcript level in a miRNA-dependent manner (Figs. 2e and 2f) , there was no significant effect on PTEN protein levels (Supporting Information Fig. 3c ). These results suggest that there is no reciprocal regulation of PTEN by the MALAT1 transcript, but that PTEN indeed regulates MALAT1 levels in a miRNA-dependent manner.
MALAT1 is regulated by the PTEN-targeting miRNAs miR-17, 20a and 106b
To examine the potential miRNA-dependent regulation of MALAT1 by PTEN, we performed bioinformatics analysis to identify predicted miRNAs that may target both PTEN and MALAT1 transcripts (Fig. 3a) . 31 We shortlisted miRNAs that are validated to target PTEN and upregulated in CRC 32, 33 and breast cancer, 34, 35 for further studies: miR-17-5p, 20a-5p, 106b-5p ( Fig. 3b; Supporting Information Figs. 4a and 4b) . Overexpression of the shortlisted miRNAs significantly downregulated the transcript levels of both PTEN and Fig. 3c; Supporting Information Fig. 4c) . In addition, they significantly reduced the activity of a luciferase reporter construct comprising the MALAT1 microRNA response element (MRE) downstream of luciferase ( Fig. 3d;  Supporting Information Fig. 4d) . Critically, mutating several residues in the seed region of the MRE resulted in a complete rescue of miRNA suppression, suggesting that the predicted MRE is indeed a bona fide target site for miR-17, 20a and 106b (Fig. 3d) .
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To further validate this, we performed biotinylated miRNA pulldowns for these three miRNAs. Real-time PCR analysis showed that both PTEN and MALAT1 transcripts were significantly enriched in all three pulldowns (Figs. 3e  and 3f ). Taken together, these results indicate that these PTEN-targeting miRNAs also target MALAT1, and suggest that PTEN may regulate MALAT1 expression at least in part via sequestering these shared miRNAs.
MALAT1 and miR-17, 20a, 106b localize to the nucleus and perinuclear space MiRNAs are well established to exert their regulatory roles predominantly in the cytoplasm. 36 MALAT1, on the other hand, is widely reported to be a nuclear lncRNA that is mainly localized to the nuclear paraspeckles alongside splicing regulators, 37 thereby suggesting the possibility that miR-17, 20a and 106b may target MALAT1 within the nucleus. Nuclear-cytoplasmic fractionation of HCT116 cells demonstrated that MALAT1 was highly abundant in the nuclear fraction, consistent with previous reports (Fig. 4a) . PTEN, miR-17a and 106b were detected in both nuclear and cytoplasmic fractions, even though approximately a third of these miRNAs was present in the nuclear fraction (Figs.  4a and 4b ). On the other hand, miR-20a was found to be approximately equal in abundance in both the nuclear and cytoplasmic fractions (Fig. 4b) . The efficiency of nuclear-cytoplasmic fractionation was validated with western blot analysis of nuclear marker histone H3 and cytoplasmic marker a-tubulin (Fig. 4c) .
In line with the fractionation data, we performed in situ hybridization and detected a predominant localization of MALAT1 in the nucleus and perinuclear space in HCT116 cells (Supporting Information Fig. 5 ). In addition, we observed a higher abundance of miR-20a in the nucleus compared to miR-17 and 106b, both of which were mainly detected in the perinuclear and cytoplasmic space (Supporting Information Fig. 5 ). Taken together, the data suggest that MALAT1 and the miRNAs are found in the same subcellular compartments, hence supporting the possibility that miR-17, 20a and 106b target MALAT1 in the perinuclear space as well as in the nucleus of HCT116 cells.
MALAT1 possesses tumor suppressive properties in colorectal and breast cancers
Overexpression of MALAT1 has been shown to enhance migration and invasion in several cancers such as lung and hepatocellular carcinoma, 38, 39 suggesting that this lncRNA plays key oncogenic roles in specific contexts. However, as our study suggests that MALAT1 is significantly downregulated in CRC and breast cancer, and positively regulated by PTEN, we hypothesized that MALAT1 may act as a hitherto uncharacterized tumor suppressor.
Cell proliferation and viability assays demonstrated no significant increase in anchorage-dependent growth upon MALAT1 knockdown (Supporting Information Figs. 6a and  6b) . However, soft agar assays showed that MALAT1 knockdown resulted in a small but significant increase in anchorageindependent growth (Supporting Information Fig. 6c ). More interestingly, migration assays such as the transwell migration chamber assay, wound-healing assay and radius cell migration assay consistently demonstrated a significant increase in the migration of CRC cells upon MALAT1 knockdown (Figs. 5a-5c ). In addition, we observed a significant increase in the invasiveness of the CRC cells following MALAT1 knockdown using the transwell invasion assay (Fig. 5d) . These results confirmed that in specific contexts, MALAT1 possesses novel tumor suppressive properties.
MALAT1 regulates expression of the pro-migratory genes EPCAM and ITGB4
To further understand the role of MALAT1 in suppressing the migratory and invasive capabilities of colon and breast cancer cells, we examined the expression levels of key migratory markers upon MALAT1 knockdown. As lncRNAs have been implicated in the regulation of gene expression via multiple mechanisms, 40 we hypothesized that MALAT1 downregulation could affect the expression of the migratory genes involved in mediating cell motility, resulting in the suppression of cancer cell migration and invasion. Upon MALAT1 knockdown, we observed a significant increase in the protein levels of EpCAM and ITGB4, two pro-migratory genes that play important roles in increasing the aggressiveness of cancer cells (Fig. 5e ). In addition, we examined the expression of genes that are commonly involved in antagonizing motility and migration and found that the knockdown of MALAT1 does not result in any significant changes to their expression levels (data not shown). In line with our hypothesis, these results indicate that MALAT1 is able to suppress cancer cell migration and invasion in part by modulating the expression level of pro-migratory genes such as EpCAM and ITGB4. In turn, MALAT1 modulates the protein levels of pro-migratory genes such as EpCAM and ITGB4 to suppress the aggressiveness of colon and breast cancer cells. Mean 6 SD, n 3, *p < 0.05; **p < 0.01; ***p < 0.001.
Discussion
In our study, we unveil the novel tumor suppressive properties of MALAT1 transcript in colorectal and breast cancers. This transcript is targeted by the oncogenic miR-17-5p, 20a-5p and 106b-5p to promote the aggressiveness of colon and breast cancer cells. Furthermore, we show that MALAT1 can be regulated via a miRNA-dependent mechanism by the key tumor suppressor PTEN. In turn, MALAT1 suppresses the migration and invasion capabilities of colon and breast cancer cells by modulating the expression of pro-migratory genes such as EpCAM and ITGB4 (Fig. 5f ). Our major findings are: (i) the tumor suppressive properties of MALAT1 in colon and breast cancers, (ii) the regulation of MALAT1 by PTEN in a miRNA-dependent manner, (iii) the potential regulation of genes that are frequently implicated in migration and invasion of cancer cells, such as EpCAM and ITGB4, by the MALAT1 transcript. In line with our findings, PTEN and MALAT1 expression levels are constantly reduced across the multiple CRC and breast cancer datasets as shown above. While the positive correlations between PTEN and MALAT1 expression in some of the datasets range from 0.03 to 0.30, we do however observe a consistent trend pointing towards a downregulation of both PTEN and MALAT1 expression across these datasets with a large cohort size.
In contrast to the oncogenic characteristics of MALAT1 in other malignancies such as lung and liver cancers, 38, 39 MALAT1 exerts the opposite effects of repressing the migration and invasion of colon and breast cancer cells, suggesting the cancer typespecific role of MALAT1 in tumorigenesis. In line with our findings, independent studies have also demonstrated tumor suppressive properties of MALAT1 in reducing proliferation and colony formation of glioma and breast cancer cells. [41] [42] [43] In our study, we have demonstrated the direct binding and downregulation of MALAT1 transcript by oncogenic miRNAs, in particular miR-17 and 20a that belong to the well-characterized protooncogenic miR17-92 cluster. 44, 45 This represents a novel mechanism by which MALAT1 exerts its noncanonical tumor suppressive role in colon and breast cancer.
Conventionally, miRNA-mediated gene silencing has been shown to occur in the cytoplasmic compartment where pre miRNAs undergo further processing to become mature miRNAs. However, increasing evidence has demonstrated the translocation of mature miRNAs back into the nucleus cytoplasm 46, 47 as well as the presence of Argonaute proteins in the nucleus, 48 suggesting that miRNA-induced regulation of gene expression may also occur in the nucleus. Indeed, recent evidence has shown that predominantly nuclear localized lncRNAs can be direct targets of miRNAs. 49, 50 In particular, nuclear-localized MALAT1 has been shown to be targeted by miRNAs for degradation in Hodgkin Lymphoma cells. 51 Critically, the miRNA-induced suppression of MALAT1 was accompanied by significant phenotypic alterations of cancer cells. 52 In line with these findings, we demonstrated that MALAT1 can potentially be targeted by the oncogenic miRNAs in the nuclear and perinuclear space of HCT116 cells.
To date, the majority of studies conducted to identify miRNA sponges rely on transient knockdown experiments. In our case, identification of the PTEN:MALAT1 regulation is based upon the stable knockout or knockdown of PTEN. As MALAT1 is conserved between human and mouse, the usage of both human cancer and mouse datasets further strengthened the significance and relevance of the PTEN:MA-LAT1 regulatory axis.
In our study, we have demonstrated that MALAT1 may potentially regulate critical cell-motility genes such as EpCAM and ITGB4 to supress the migration and invasion of colon and breast cancer cells. First discovered as a dominant cell surface marker in colorectal carcinomas, EpCAM has been shown to possess oncogenic ability by promoting the upregulation of cmyc and cyclins A and E [53] [54] [55] as well as suppressing E-cadherin. 56 On the other hand, elevated expression of ITGB4 has been implicated in increased aggressiveness of carcinomas and malignancies. 57 Our data suggest that MALAT1's ability to impede the aggressiveness of colon and breast cancer cells is in part due to its capacity to modulate the expression of these promigratory genes. Further experiments will have to be performed to unveil the mechanisms underlying this potential regulation.
In conclusion, we have revealed a novel tumor suppressive role of the lncRNA MALAT1 in suppressing the migration and invasion capabilities of colon and breast cancer cells via the modulation of pro-migratory genes such as EpCAM and ITGB4. More importantly, we show that the key tumor suppressor PTEN may regulate the expression of MALAT1 by potentially sponging shared, oncogenic miRNAs. Our study highlights the context-dependent characteristics of lncRNAs and sheds light on the intricate crosstalk between key protein coding genes and lncRNAs in affecting tumorigenesis.
